Söndag 10 Maj | 16:33:11 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-16 08:30 Bokslutskommuniké 2026
2026-11-03 08:30 Kvartalsrapport 2026-Q3
2026-09-01 08:30 Kvartalsrapport 2026-Q2
2026-05-29 N/A X-dag ordinarie utdelning IZAFE B 0.00 SEK
2026-05-28 N/A Årsstämma
2026-04-28 - Kvartalsrapport 2026-Q1
2026-03-12 - Extra Bolagsstämma 2026
2026-02-16 - Bokslutskommuniké 2025
2025-11-03 - Kvartalsrapport 2025-Q3
2025-08-29 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder bland annat en läkemedelsrobot, SaaS-lösningar och en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare globalt. iZafe Group har sitt huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-05-08 13:30:00

April was characterized by a high level of activity across several areas. We continue to see strong interest in Dosell, both in Sweden and internationally, while the focus is increasingly shifting from procurement processes and dialogue to actual implementation and scaling.

During the month, we continued to strengthen the organization in order to meet growing demand and manage an increasing number of start-ups, installations and customer dialogues. The number of active Dosell units increased during the month by approximately 5 percent compared with the previous month, driven by new implementations and expansions among existing customers.

At the same time, we see clear signs that the market for medication dispensing devices continues to mature rapidly, particularly in Sweden, where the ADDA framework agreement is now creating new opportunities for municipalities and regions to initiate broader rollouts.

Sweden – Increased Activity Following ADDA
Since the ADDA framework agreement came into effect, we have seen a clear increase in interest from municipalities that are now evaluating how Dosell can be implemented on a larger scale. Several municipalities are planning call-offs under the framework agreement, and we are engaged in ongoing dialogues regarding upcoming implementations.

During April, we continued to carry out a large number of demonstrations, start-ups and customer meetings. We also see that several processes are moving faster than before, with some municipalities now progressing from initial dialogue to decision within a significantly shorter timeframe.

We have also demonstrated Dosell to a first major municipality through ADDA and are now awaiting feedback on the next steps in the process.

At the same time, more municipalities are continuing to move from pilot projects to broader deployment. This confirms that medication dispensing devices are increasingly being viewed as a natural part of future medication management and preventive care.

Vitalis – Strong Interest in Medication Dispensing Devices
At the beginning of May, we participated for the first time with our own booth at Vitalis, the largest e-health and welfare technology exhibition in the Nordic region. The event was highly successful, and we held a large number of meetings with municipalities, regions and collaboration partners.

A clear trend from this year’s exhibition was that medication dispensing devices are now a prioritized area for many municipalities and regions. The ADDA framework agreement has contributed to increased visibility for the topic, and several presentations and discussions during the event focused on the benefits of digital medication management and how municipalities are working to strengthen independence and safety for users.

Among other things, results were presented from municipalities already using medication dispensing devices, showing very high levels of perceived safety and independence.

The Netherlands – Continued Focus on Scaling
In the Netherlands, we continue to build for long-term growth. The organization has been strengthened with additional resources to manage more implementations and a higher pace of scaling in the coming quarters.

During April, we continued dialogues with both new and existing care organizations regarding the scaling of Dosell. A particular focus is on integrations and simplified implementation flows, which are key to scaling the solution efficiently in the Dutch market.

Finland and Other Markets
We continue our work in Finland, where we submitted a major tender in April with significant potential. At the same time, dialogues and activities continue together with our partners in Norway, Iceland and Spain.

Across several markets, we see the same overall trend as in Sweden: an increasing focus on digitalization, independence and more efficient medication management within healthcare and social care.

Product, Quality and Scalability
To meet the increasing activity level and prepare for more parallel start-ups, we have strengthened the organization within implementation, support, technology and quality assurance. The purpose is to reduce lead times, improve onboarding and ensure stable operations as Dosell is scaled across more markets.

We also continue to develop our platform and workflows with a focus on scalability, user experience and stability. Among other things, further work has been carried out on our remote care platform and new onboarding flows.

Looking Ahead – From Pipeline to Implementation
After a period focused on tenders, partnerships and market development, we are now entering a phase where implementation and scaling are becoming increasingly important. In the coming months, the work will primarily focus on converting the increased interest into concrete start-ups, more active units and scalable implementations.

Our priorities going forward are to:

  • Carry out start-ups and implementations in new municipalities
  • Continue the work with call-offs through ADDA
  • Drive scaling in the Netherlands
  • Strengthen the organization in line with growth
  • Continue developing our international partner dialogues

We remain committed to working long term and purposefully to make Dosell a natural part of the future of medication management.

Thank you for following our journey.